Belle, R., F. Baska, Z. Orfi, C. Szantai-Kis, A. Sipos, N. Breza, G. Borbely, K. Penzes, L. Orfi and G. Keri: Characterization of p53 activator compounds which inhibit a survival factor kinase as well. In: FEBS Journal 279, Suppl. 1 Sp. Iss., 179-179 (2012).
Keri, G., L. Orfi, Z. Greff, Z. Varga, B. Szokol, Z. Horvath, I. P. Petak and A. Ullrich: SIGNAL TRANSDUCTION THERAPY OF TUMORS WITH MULTIPLE TARGET KINASE INHIBITORS. In: Anticancer Research 28, 5C, (2008).
Zhang, Y. X., P. G. Knyazev, Y. V. Cheburkin, K. Sharma, Y. P. Knyazev, L. Orfi, I. Szabadkai, H. Daub, G. Keri and A. Ullrich: AXL is a potential target for therapeutic intervention in breast cancer progression. In: Cancer Research 68, 6, 1905-1915 (2008).
Keri, G., L. Orfi, D. Eros, B. Hegymegi-Barakonyi, C. Szantai-Kis, Z. Horvath, F. Waczek, J. Marosfalvi, I. Szabadkai, J. Pato, Z. Greff, D. Hafenbradl, H. Daub, G. Muller, B. Klebl and A. Ullrich: Signal transduction therapy with rationally designed kinase inhibitors. In: Current Signal Transduction Therapy 1, 1, 67-95 (2006).
Szantai-Kis, C., I. Kovesdi, D. Eros, P. Banhegyi, A. Ullrich, G. Keri and L. Orfi: Prediction oriented QSAR modelling of EGFR inhibition. In: Current Medicinal Chemistry 13, 3, 277-287 (2006).
Godl, K., O. J. Gruss, J. Eickhoff, J. Wissing, S. Blencke, M. Weber, H. Degen, D. Brehmer, L. Orfi, Z. Horvath, G. Keri, S. Muller, M. Cotten, A. Ullrich and H. Daub: Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. In: Cancer Research 65, 15, 6919-6926 (2005).
Blencke, S., B. Zech, O. Engkvist, Z. Greff, L. Orfi, Z. Horvath, G. Keri, A. Ullrich and H. Daub: Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. In: Chemistry & Biology 11, 5, 691-701 (2004).
The Max Planck Society does not take any responsibility for the content of this export.